Published in Clin Cancer Res on September 21, 2010
Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci Transl Med (2013) 2.03
Molecular pathways: targeted α-particle radiation therapy. Clin Cancer Res (2012) 1.24
Clinical radioimmunotherapy--the role of radiobiology. Nat Rev Clin Oncol (2011) 1.10
Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia. Blood (2017) 1.09
Radioimmunotherapy of human tumours. Nat Rev Cancer (2015) 1.07
Emerging therapeutic drugs for AML. Blood (2015) 1.04
Novel drugs for older patients with acute myeloid leukemia. Leukemia (2014) 0.99
Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis. Eur J Nucl Med Mol Imaging (2012) 0.93
The potential and hurdles of targeted alpha therapy - clinical trials and beyond. Front Oncol (2014) 0.90
A Critical Review of Alpha Radionuclide Therapy-How to Deal with Recoiling Daughters? Pharmaceuticals (Basel) (2015) 0.88
The elements of life and medicines. Philos Trans A Math Phys Eng Sci (2015) 0.88
Targeting aberrant DNA double-strand break repair in triple-negative breast cancer with alpha-particle emitter radiolabeled anti-EGFR antibody. Mol Cancer Ther (2013) 0.88
Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb. PLoS One (2013) 0.87
Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle. Expert Opin Biol Ther (2016) 0.85
Microdosimetry for targeted alpha therapy of cancer. Comput Math Methods Med (2012) 0.83
Advances in the treatment of hematologic malignancies using immunoconjugates. Blood (2014) 0.83
Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia. Semin Hematol (2013) 0.82
Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model. Blood (2013) 0.81
Alpha-particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenation. PLoS One (2013) 0.81
In vitro cytotoxicity of surface modified bismuth nanoparticles. J Mater Sci Mater Med (2012) 0.80
α-Radioimmunotherapy with ²¹³Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma. Oncotarget (2015) 0.79
Immunotherapy in pediatric malignancies: current status and future perspectives. Future Oncol (2014) 0.78
Radiopharmaceutical therapy in the era of precision medicine. Eur J Cancer (2014) 0.78
Radiolabeled antibodies directed at CD45 for conditioning prior to allogeneic transplantation in acute myeloid leukemia and myelodysplastic syndrome. Ther Adv Hematol (2012) 0.77
Target Therapy in Hematological Malignances: New Monoclonal Antibodies. Int Sch Res Notices (2014) 0.76
Targeted alpha anticancer therapies: update and future prospects. Biologics (2014) 0.76
Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplant (2015) 0.76
Quantitative single-particle digital autoradiography with α-particle emitters for targeted radionuclide therapy using the iQID camera. Med Phys (2015) 0.76
Combination of Antiretroviral Drugs and Radioimmunotherapy Specifically Kills Infected Cells from HIV-Infected Individuals. Front Med (Lausanne) (2016) 0.75
Long-Term Toxicity of 213Bi-Labelled BSA in Mice. PLoS One (2016) 0.75
Targeting Prostate Cancer Stem Cells with Alpha-Particle Therapy. Front Oncol (2017) 0.75
Targeted alpha therapy of mCRPC: Dosimetry estimate of (213)Bismuth-PSMA-617. Eur J Nucl Med Mol Imaging (2017) 0.75
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis (1987) 174.79
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol (2003) 17.67
Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med (1998) 5.98
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol (2000) 3.38
Tumor therapy with targeted atomic nanogenerators. Science (2001) 2.48
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer (2005) 2.08
Targeted alpha particle immunotherapy for myeloid leukemia. Blood (2002) 1.99
Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med (1999) 1.95
A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res (1984) 1.85
Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates. Bioconjug Chem (1992) 1.68
Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. J Nucl Med (1999) 1.42
Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. Blood (1983) 1.23
Radiometal labeling of immunoproteins: covalent linkage of 2-(4-isothiocyanatobenzyl)diethylenetriaminepentaacetic acid ligands to immunoglobulin. Bioconjug Chem (1991) 1.20
Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer (2007) 1.19
A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies. Nucl Med Biol (1995) 1.07
Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res (1992) 1.06
A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood (1994) 1.03
Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia. Clin Cancer Res (1998) 1.01
An 225Ac/213Bi generator system for therapeutic clinical applications: construction and operation. Appl Radiat Isot (1999) 0.97
Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant (2003) 0.95
Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial. Leuk Lymphoma (2009) 0.94
Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use. J Nucl Med (1999) 0.93
Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia (2003) 0.90
Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clin Cancer Res (2000) 0.87
Parametric images of antibody pharmacokinetics in Bi213-HuM195 therapy of leukemia. J Nucl Med (2001) 0.85
Cytosine arabinoside (NSC-63878) therapy for acute leukemia in adults. Cancer Chemother Rep (1969) 0.83
Chemotherapy of acute leukemia. Comparison of cytarabine alone and in combination with vincristine, prednisone, and cyclophosphamide. Arch Intern Med (1974) 0.82
Cytarabine for acute leukemia in adults. Effect of schedule on therapeutic response. Arch Intern Med (1974) 0.78
Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med (2006) 4.71
Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res (2007) 4.42
How to build and interpret a nomogram for cancer prognosis. J Clin Oncol (2008) 4.24
Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res (2005) 3.71
Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol (2005) 3.51
KIT as a therapeutic target in metastatic melanoma. JAMA (2011) 3.49
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. J Nucl Med (2007) 3.08
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer (2010) 3.03
Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol (2006) 2.99
MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry--standardization of nomenclature. J Nucl Med (2009) 2.92
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A (2011) 2.90
Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol (2007) 2.83
89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med (2010) 2.82
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol (2005) 2.75
A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res (2003) 2.73
Hospital and surgeon procedure volume as predictors of outcome following rectal cancer resection. Ann Surg (2002) 2.71
Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol (2004) 2.66
Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET. J Nucl Med (2003) 2.62
Clinicopathological features of and risk factors for multiple primary melanomas. JAMA (2005) 2.62
Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev (2007) 2.60
Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood (2011) 2.59
Developing a cancer-specific geriatric assessment: a feasibility study. Cancer (2005) 2.57
124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med (2003) 2.44
Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol (2011) 2.42
Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response. J Nucl Med (2003) 2.33
Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol (2006) 2.32
Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab (2005) 2.30
A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol (2012) 2.27
Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol (2012) 2.26
Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. Radiology (2013) 2.24
Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J Nucl Med (2006) 2.24
Patterns of care in elderly glioblastoma patients. Ann Neurol (2008) 2.17
Association between incident cancer and subsequent stroke. Ann Neurol (2015) 2.13
Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer. Nucl Med Commun (2013) 2.12
Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med (2004) 2.05
Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol (2003) 2.04
Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci Transl Med (2013) 2.03
Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection. J Natl Cancer Inst (2006) 2.01
(124)I-huA33 antibody PET of colorectal cancer. J Nucl Med (2011) 2.01
Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med (2012) 2.00
N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res (2008) 2.00
Targeted alpha particle immunotherapy for myeloid leukemia. Blood (2002) 1.99
Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol (2006) 1.98
Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase. Nat Med (2009) 1.98
Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res (2008) 1.98
Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res (2005) 1.97
Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest (2011) 1.97
The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res (2005) 1.97
Fluorescent silica nanoparticles with efficient urinary excretion for nanomedicine. Nano Lett (2009) 1.97
Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res (2008) 1.94
Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol (2012) 1.93
Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J Clin Invest (2011) 1.91
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. Mol Imaging Biol (2015) 1.90
Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys (2005) 1.89
Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. Cancer Discov (2012) 1.87
Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes. Nat Biotechnol (2003) 1.87
Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A (2011) 1.87
Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model. Cancer Biol Ther (2007) 1.85
Cancer screening among patients with advanced cancer. JAMA (2010) 1.82
Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med (2008) 1.82
Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison. J Nucl Med (2004) 1.81
Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. Cancer Res (2010) 1.80
Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. Blood (2010) 1.77
Desmoplastic melanoma: a pathologically and clinically distinct form of cutaneous melanoma. Ann Surg Oncol (2005) 1.76
Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med (2004) 1.76
Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up. J Clin Oncol (2008) 1.75
Measurement of lung tumor motion using respiration-correlated CT. Int J Radiat Oncol Biol Phys (2004) 1.74
Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol (2007) 1.74
Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry. J Nucl Med (2007) 1.73
Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection. J Surg Oncol (2003) 1.73
Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol (2008) 1.73
Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software. J Nucl Med (2007) 1.72
Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. Leuk Res (2013) 1.70
2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res (2011) 1.69
Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med (2007) 1.69
Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res (2010) 1.67
Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res (2005) 1.67
Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg (2002) 1.66
Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for Locoregional advanced head and neck cancer. J Nucl Med (2008) 1.65
18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions. J Nucl Med (2010) 1.63